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’INTRODUCTION
Strategiestodirectcellularfunctionsinbiomaterialsviaspatial
and temporal delivery of proteins, such as growth factors,
chemokines, and cytokines, are of growing interest in tissue
engineering applications. These biomacromolecules can control
cell diﬀerentiation, proliferation, migration, and even apoptosis.
1-6
However, dosing and targeting of proteins to speciﬁc cell pop-
ulations can pose signiﬁcant challenges. For example, growth
factors are eminently potent and can elicit a variety of cellular
responses at picomolar concentrations.
4 Further, many factors
are cross-reactive across a multitude of cells and tissue types and
areknown tohave shorthalf-lives invivo.
6Toovercome someof
theselimitations, a biomaterial delivery platform was explored to
facilitate greater control over the bioactivity and availability of
growth factors, particularly transforming growth factor beta
(TGFβ1),deliveredlocallytotargetedcellpopulationsortissues.
TGFβ1, a member of the TGF superfamily, regulates many
cellular process including proliferation, diﬀerentiation, chemo-
taxis, and tumorigenesis.
4 TGFβ1 is known to play a crucial role
in promoting chondrogenic diﬀerentiation of human mesench-
ymal stem cells,
7-10 guiding the organization of endothelial cells
in angiogenesis,
11 and regulating the extracellular matrix produc-
tion of valvular smooth muscle cells.
12 Because many cells express
TGFβ1 receptors, a local delivery platform is often required for
spatial and temporal control over its dosage. One method for
controlling the delivery of growth factors is through encapsula-
tion inpolymeric matrices, such as poly(ethyleneglycol) (PEG).
PEG hydrogels have been used to deliver a variety of growth
factors; however, a great challenge facing PEG hydrogels cross-
linked by chain growth polymerizations is the potential for
irreversible protein damage.
13
Formanyproteindeliveryapplications,directencapsulationof
growthfactors (i.e., through the inclusion of the target protein in
themonomerprecursorsolution)isdesirableduetoitssimplicity
in preparation and a facile control of the total growth factor
payload. Photoinitiated reactions are commonly used in cell
encapsulation schemes, due to their mild reaction conditions,
speciﬁcally physiological pH, temperatures, and osmolarity.
While these characteristics render a photoinitiated polymeriza-
tion system desirable for the formation of cell-laden hydrogels,
they are known to create adverse reactions to protein therapeu-
tics, which are usually unstable and can be easily denatured. For
example,growthfactorspresentintheformationofhydrogelsare
susceptible to damage during the reaction, primarily due to the
presence of highly reactive radical species
14 generated by clea-
vage of photoinitiator species. In addition to initiating polymer-
ization reactions, these free radicals may undergo a number of
nonspeciﬁc side reactions with functional groups associated with
aminoacids,includingphenols,thiols,anddisulﬁdes,
15leadingto
either direct conjugation of the growth factor to the polymer
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ABSTRACT: Transforming growth factor beta (TGFβ1)i n ﬂuences a
host of cellular fates, including proliferation, migration, and diﬀerentia-
tion. Due to its short half-life and cross reactivity with a variety of cells,
clinical application of TGFβ1 may beneﬁt from a localized delivery
strategy. Photoencapsulation of proteins in polymeric matrices oﬀers
such an opportunity; however, the reactions forming polymer networks
often result in lowered protein bioactivity. Here, PEG-based gels formed
from the chain polymerization of acrylated monomers were studied as a
model system for TGFβ1 delivery. Concentrations of acrylate group
ranging from 0 to 50 mM and photopolymerization conditions were systematically altered to study their eﬀects on TGFβ1
bioactivity. In addition, two peptide sequences, WSHW (KD = 8.20 nM) and KRIWFIPRSSWY (KD = 10.41 nM), that exhibit
bindingaﬃnityforTGFβ1wereintroducedintothemonomersolutionpriortoencapsulationtodetermineifaﬃnitybinderswould
increase the activity and release of the encapsulated growth factor. The addition of aﬃnity peptides enhanced the bioactivity of
TGFβ1 in vitro from 1.3- to 2.9-fold, compared to hydrogels with no peptide. Further, increasing the concentration of aﬃnity
peptides by a factor of 100-10000 relative to the TGFβ1 concentration increased fractional recovery of the protein from PEG
hydrogels.1052 dx.doi.org/10.1021/bm101379v |Biomacromolecules 2011, 12, 1051–1057
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backbone or loss of protein conformation and, therefore,
bioactivity.
13 The development of an encapsulation scheme to
ameliorate potential radical damage would, therefore, be desir-
able to enhance the eﬃcacy of polymeric growth factor delivery
platforms.
Anumberofpolymericmaterials have been utilized asprotein
delivery vehicles, including alginate,
16 collagen,
17 PLGA,
18 and
PEG.
18 Recent work demonstrates the use of novel polymeric
materials incorporating aﬃnity ligands for sustained protein
release through mixed-mode, thiol-acrylate polymerizations.
19-21
These systems utilize ligands that noncovalently and reversibly
interact with the target protein, with release being tuned by both
diﬀusion and the binding kinetics unique to the ligand-protein
pair. Speciﬁc peptide-ligand systems, where the peptide ligand
has aﬃnity for a unique protein, have been shown eﬀective for
controlled release of bFGF
19 and sequestration of MCP-1
20 and
TNFR.
21Nonspeciﬁcligandssuchasheparinandalginatesulfate
employ electrostatic aﬃnity interactions present on numerous
proteins;
22 such ligands, when added to hydrogel systems, have
been utilized to govern release of many growth factors,including
bFGF,
23 NGF,
24 VEGF,
25,26 PDGF-BB,
26,27 and TGFβ1.
26-28
We hypothesized that the presence of free radicals generated
during photoinitiated polymerizations would induce TGFβ1
structural and functional damage, and that the inclusion of aﬃnity
binding peptides during photopolymerization could prevent
some of this damage. Using photo-cross-linked PEG hydrogels
as a platform, we systematically studied the inﬂuence of photo-
polymerization conditions on TGFβ1 bioactivity and availability.
Quantiﬁcation of released TGFβ1 was determined by ELISA,
whileconﬁrmationofTGFβ1bioactivitywasachievedviaaTGF-
receptor reporter cell line. Further, we analyzed the binding
aﬃnity of the TGFβ1 peptide ligands, Trp-Ser-His-Trp
29 and
Lys-Arg-Ile-Trp-Phe-Ile-Pro-Arg-Ser-Ser-Trp-Tyr,
30 using sur-
face plasmon resonance studies. These aﬃnity peptides were
included in monomer solutions during photoencapsulation of
TGFβ1, and the enhancement of TGFβ1 recovery from photo-
polymerized PEG hydrogels was examined. The dose dependence
of the peptide/TGFβ1 ratio on protein recovery and bioavail-
ability from PEG hydrogels was also studied and quantiﬁed for
both aﬃnity sequences.
’EXPERIMENTAL SECTION
Materials. All chemicals were purchased from Sigma-Aldrich unless
otherwise noted.
PEGDA Synthesis. Poly(ethylene glycol) diacrylate (PEGDA)
monomers were prepared as previously described.
18 Briefly, hydroxyl-
terminated poly(ethylene glycol) (Mn = 4600, 6000, or 10000 Da) was
reacted with acryloyl chloride in the presence of triethylamine under
argon for overnight. The product solution was filtered through neutral
alumina oxide and stirred for 2 h in sodium carbonate. After an addi-
tionalfilteringstep,excesstoluenewasremovedunderreducedpressure
and subsequently precipitated into cold ethyl ether.
1H NMR revealed a
degree of acrylation of at least 95% for all material used in this study.
Solid Phase Peptide Synthesis. All peptides were synthesized
using a solid phase peptide synthesizer (Applied Biosystems 433A) and
standard Fmoc chemistry. Peptide cleavage solution was formed by
dissolving250mgdithiothreitoland250mgphenolinasolutionof95%
trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS), and 2.5%
deionized water. Synthesized peptides were cleaved in the solution for
2 h. Cleaved peptides were precipitated in cold ethyl ether and desiccated
overnight, followed by reverse-phase HPLC (Waters Delta Prep 4000)
purification. The collected fractions of purified peptides were identified
by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-
TOF) mass spectrometry (Supporting Information).
TGFβ1PhotodestructionStudies.RecombinanthumanTGFβ1
solutions(Peprotech)(finalconcentration:2nM)werepreparedinPBS
in the presence of 1 mM lithium phenyl-2,4,6-trimethylbenzoylphos-
phinate
31 (LAP) initiator and varying concentrations of poly(ethylene
glycol) monoacrylate (Monomer-Polymer and Dajac Laboratories; Mn =
2000Da).SolutionswereexposedtoUVlight(Omnicure365nm)atan
intensity of 10 mW/cm
2 for 3 min. Following UV exposure, TGFβ1
solutions were analyzed with a Human/Mouse TGFβ1 ELISA kit
(eBioscience) to determine the recovery of intact TGFβ1
TGFβ1 Release from PEG Hydrogels. Human TGFβ1 at a final
concentration of 25 nM was photoencapsulated in 10 wt % PEG (Mn =
10000 Da) hydrogels. For affinity peptide formulations, TGFβ1 binding
peptides WSHWor KRIWFIPRSSWY were also incorporated. Peptides
wereincludedatamolarratio,R,relativetoTGFβ,equalto100,1000,or
10000. Growth factor release studies were conducted in release buffer
(1 mM EDTA and 0.05% BSA in PBS) in scintillation vials pretreated
with SigmaCote to reduce nonspecific protein absorption on the wall of
the vials. Supernatants were collected at predetermined time points and
replaced with fresh release buffer. Concentrations of released TGFβ1
were determined by ELISA.
TGFβ1 Bioactivity Assay. TGFβ1 bioactivity was confirmed with
PE.25 cells stably transfected with a luciferase reporter gene. The assay
was performed as reported previously.
32 Briefly, PE.25 cells were plated
in 12-well plates (200000 cells/well) and incubated in serum-free
DMEM media. PEGDA hydrogels (Mn = 10000 Da) encapsulated with
25 nM TGFβ1 were placed in coculture with cells for 24 h at 37 C and
5% CO2. Cells were lysed in lysis buffer (Promega) and frozen at -
80 C for greater than 2 h. Lysate was centrifuged at 15000 rpm at 4 C
for 10 min and supernatant collected and added to luciferase substrate
(Promega). Luminescence was measured using Perkin-Elmer 1420
spectrophotometer.
Surface Plasmon Resonance Binding Studies. A Biacore
3000 instrument (GE Healthcare) and research grade carboxymethyl-
dextran functionalized (CM5) biosencor chips (GE Healthcare) were
used for all studies. The flowcell surfaces were equilibrated in HBS-EP
running buffer and preconditioned with NaOH, HCl, SDS and H3PO4.
Flowcell surfaces were activated with a solution of 0.25 M n-hydro-
xysuccinimide and 0.5 M N-ethyl-N0-(dimethylaminopropyl) carbodii-
mide hydrochloride, followed by injection of 6.2 mM N-phenyldie-
thanalamine in 0.1 M borate buffer. Flowcells were then injected with
ligand-functionalized affinity peptides in acetate buffer, and all surfaces
were then deactivated with a solution of L-cysteine/NaCl in 100 mM
sodium formate buffer.
After allowing the ﬂowcell surfaces to equilibrate with HBS-EP
running buﬀer, solutions of varying concentrations of TGFβ1, diluted
in HBS-EP buﬀer, were injected using kinetic analysis injection proto-
cols through Biacontrol software. All data was analyzed using Scrubber2
software (BioLogic Software).
Statistics. All data are reported as a mean ( s.e.m. based on three
repeats per experimental condition, unless otherwise noted.
’RESULTS AND DISCUSSION
Effect of Network Cross-Linking Density on TGFβ1 Re-
lease. Varying cross-linking density (or mesh size) in hydrogel
matrices provides a facile method to control protein diffusivity,
andingeneral,theratioofproteindiffusivityinanetworkrelative
to that in a pure solvent scales with (1 - Rh/ξ).
33 Here, Rh is
theprotein radiusandξisthenetworkmeshsize.Asanexample,
the mesh size of PEG hydrogels can be tailored by varying the
molecularweightofPEGDAatadefinedweightcontent.Figure11053 dx.doi.org/10.1021/bm101379v |Biomacromolecules 2011, 12, 1051–1057
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shows fractional release of TGFβ1 encapsulated in 10 wt % PEG
hydrogels of varying molecular weights. Interestingly, hydrogels
of PEGDA 4600 Da and 6000 Da released less than 5% of the
encapsulated protein over a two day period, while 10 wt %
PEGDA 10000 Da gels released approximately 25% of the
TGFβ1 payload over the same time frame. To determine if the
lower TGFβ1 release from PEGDA 4600 and 6000 Da gels was
due to hindered diffusivity in the more cross-linked hydrogels,
the average mesh size of these gels was estimated from equilib-
rium swelling ratios using a modified Flory-Rehner method
34
(Table 1).
While the hydrodynamic radius of TGFβ1 has not been
reported in the literature, proteins of similar molecular weight,
including chymotrypsinogen
35 and enhanced green ﬂuorescent
protein,
36 have reported radii on the order of 28-35 Å (Sup-
porting Information). However, because no appreciable amount
of TGFβ1 encapsulated in PEGDA 4600 and 6000 was released
over a two day period, mesh size was not likely the principal
determinant of TGFβ1 release in this system. In comparing the
three hydrogel formulations used, the photoinitiator concentra-
tion and UV exposure conditions were identical, as were the
monomer concentrations relative to the TGFβ1 concentration.
Duetotheuseofaconstantweight/volumeformulation,acrylate
concentrations were not held constant (Table 2), and the eﬀect
of this factor on TGFβ1 release warranted further investigation,
particularly because the rate of polymerization scales directly
with the acrylate concentration to a ﬁrst approximation.
Effect of Acrylate Concentration on TGFβ1 Recovery in
Solution.To characterize the effect of acrylate concentration on
TGFβ1 recovery during photoinitiated reactions, a PEG mono-
acrylate (PEGMA) monomer was selected. At low concentra-
tions, similar to those used for hydrogel formation with the
diacrylated PEG, monoacrylates do not form a cross-linked
polymerwhenexposedtoUVradiationinthepresenceofphoto-
initiators. Photoinitiated radicals can propagate through the
acrylate group, and polyacrylate kinetic chains are formed via a
chain polymerization, but the polymer remains soluble. This
aspect makes PEGMA ideal for use in modeling the PEGDA-
protein encapsulation reaction scheme.
13,37 Proteins photoen-
capsulatedinPEGDAmaybecovalentlyconjugatedtothepolymer,
resulting in a loss of soluble protein in solution. Alternatively,
irradiated solutions of PEGMA and TGFβ1 may lead to radical
mediated damage through chain transfer, and the solutions can
be subsequently assayed for protein concentration or bioactivity.
Reductionsineitherfactorareattributedtotheeffectsofreaction
conditions.
Solutions of TGFβ1 and photoinitiator, with varying concen-
trationsofPEGMA,wereexposedtoUVdosagesidenticaltothat
used for photoencapsulation with diacrylate PEGDA. The inﬂu-
ence of the polymerization conditions on TGFβ1 recovery after
UV exposure was tested via ELISA on diluted solution samples,
which showed increased growth factor recovery with increasing
acrylate concentration. Maximum postirradiation recovery of
TGFβ1 greater than 90% was found for acrylate concentrations
above 40 mM (Figure 2A). TGFβ1 recovery data via ELISA
(Figure 2a) supports results previously published on the so-called
“protective eﬀect” that increasing monomer concentrations aﬀord
proteins.
13
Interestingly, bioactivity after UV exposure was maximized at
20 mM acrylate concentration, with lower activity at both higher
and lower acrylate concentrations (Figure 2B). While loss of
bioactivity of TGFβ1 at low acrylate concentration is consistent
with data from the ELISA assays, reduced bioactivity for samples
withhighacrylate concentrations isnot.One explanationfor this
observation is potential PEGylation of the growth factor, result-
ing in a loss of bioactivity and increased hydrophilicity. Direct
detection of PEGylated TGFβ1 presents a challenge for tradi-
tional mass spectroscopic techniques, due to the biologically
relevant nanomolar concentration range used. This concentra-
tion is several orders of magnitude below the limit of detection
for HPLC, NMR, GC, and MALDI methods. PEGylated BMP-2
has been characterized qualitatively using SDS-PAGE,
38 but this
methodislimitedbylowsolubilityofhydrophobicproteins,such
as TGFβ1, in SDS solutions. While we were unable to directly
measure PEGylated TGFβ1, others have observed PEGylated
proteins during chain polymerization of PEG monoacrylate
monomers in solution with a model protein, lysozyme.
13 For
solutionstudiesusingPEGmonoacrylate,anyPEGylatedgrowth
factor remains in the reaction solution and is potentially detect-
able by ELISA techniques. However, in diacrylate systems,
PEGylated growth factors could be covalently conjugated to
the hydrogel polymer. Any conjugation would lead to signiﬁcant
reduction in the total fractional release of soluble, bioactive
TGFβ1 from the polymer. This mechanism may explain, in part,
the lower fractional release of TGFβ1 from PEGDA 4600 and
PEGDA 6000 hydrogels.
Surface Plasmon Resonance Studies Confirm TGFβ1/Pep-
tide Affinity. Affinity peptides have previously been used to
successfullycontrolthereleaseofencapsulatedproteins.
18Further,a
small soluble affinity ligand has been previously used to protect
photoencapsulated bovine serum albumin in PEG hydrogels.
37
Here, we aimed to test whether inclusion of affinity peptides in
monomer solutions could help protect proteins from radical
mediated damage and/or conjugation during photoencapsula-
tion reactions. First, surface plasmon resonance (SPR) was used
to characterize the binding affinity between each peptide se-
quence and TGFβ1. SPR technology allows precise, label-free
measurement of the formation of affinity-binding complexes
between two interacting macomolecules
39 and provides a useful
way to analyze the affinity interactions between peptides and
TGFβ1.TworeportedTGFβ1bindingpeptidesweresynthesized
with a terminal cysteine separated from the binding sequence
by two glycine spacers (CGGWSHW
29 and CGGKRIWFIRPS-
SWY
30) and then covalently linked to a dextran-functionalized
Figure 1. Fractional release of TGFβ1 as a function of time when
entrapped in PEG gels formed from the solution polymerization of
PEGDA monomers of varying molecular weight. All gels were formed
from 10 wt % monomer systems. The ﬁnal network mesh size aﬀects
TGFβ1release.WhilePEG 4600andPEG6000 gelshad noappreciable
TGFβ1 release, PEG 10000 gels had 25% fractional release over 2 days.1054 dx.doi.org/10.1021/bm101379v |Biomacromolecules 2011, 12, 1051–1057
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SPR flowcell surface using standard ligand-thiol coupling chem-
istry. After equilibrating the chip in HBS-EP running buffer,
TGFβ1 solutions of varying concentration, from 5 to 100 nM,
were injected across flow cells, and the normalized response,
proportional to the amount of peptide/TGFβ1 complex formed
on the chip surface, is reported in Figure 3. Both the KRIW-
FIPRSSWY (Figure 3a) and WSHW (Figure 3b) functionalized
flowcells exhibit the formationof affinitycomplexes with TGFβ1
and show binding in a dose-dependent manner, confirming
peptide/TGFβ1 affinity interaction. Analysis of the association
and dissociation regimes of the sensogram yielded kd, the
peptide/TGFβ1 dissociation rate constants, and KD, equilibrium
dissociation constants, as shown in Table 3. Each peptide sequence
was found to have affinity binding capacity for TGFβ1 in the
nanomolar range, qualifying each as a strong binder; however,
the KD values for the two peptides do not differ significantly.
Affinity Peptides Do Not Inhibit Bioavailability of TGFβ1.
After SPR confirmation of peptide TGFβ1 affinity, an inhibition
study was conducted to determine if peptides incubated with
TGFβ1 would interfere with extracellular TGF receptors, pre-
ventinggrowthfactorsignaling.TheWSHWandKRIWFIPRSS-
WY sequences were originally reported as TGFβ1 inhibitors, but
inhibition was demonstrated through growth factor pull-down
studies, where solutions of growth factor are incubated with
peptide tethered to a solid phase resin. A bioactivity assay was
required to investigate whether soluble peptides, complexed to
TGFβ1insolution,wouldinterfere withTGF receptor signaling.
PE.25cells,transfectedwithaluciferasereportergeneforSMAD
signaling, were incubated with solutions of WSHW, KRIW-
FIPRSSWY, and TGFβ1 (Figure 4). At a 10,000 molar excess
and a peptide with a nanomolar dissociation constant, over 99%
of the growth factor in solution will exist in the peptide:TGFβ1
affinity complex. Luciferase activity of the cell lysate was
Table 1. Equilibrium Swelling and Calculated Average Mesh
Size of Hydrogels Formed from the Solution Polymerization
of Poly(ethylene glycol) Diacrylate Monomers of Varying
Molecular Weight
PEGDA molecular
weight (Da)
mass swelling
ratio, q
volumetric swelling
ratio, Q
mesh size, ξ
(Å)
4600 17 ( 21 8 ( 2 200 ( 20
6000 24 ( 12 5 ( 1 300 ( 20
10000 29 ( 23 1 ( 2 380 ( 40
Table2. CalculatedAcrylateConcentrationsinFormulations
of Various Molecular Weight PEGDAs at 10 wt %, The
Concentrations Used To Synthesize the Hydrogel
Formulations
PEGDA molecular weight
(Da)
acrylate concentration at 10 wt % monomer
(mM)
4600 43.5
6000 33.3
10000 20
Figure 2. TGFβ1 recovery from photopolymerized acrylate solutions.
(a) In nongelling monoacrylate solutions, TGFβ1 recovery is highest at
high acrylate concentrations, as measured by ELISA. (b) Bioactivity
assays across the same acrylate concentration range show a maximum at
intermediate concentrations, as determined by reporter cell assay. Error
bars represent standard error (n = 4).
Figure 3. SPR sensorgrams for TGFβ1 injection over surfaces functio-
nalized with immobilized peptides: (a) CGGKRIWFIPRSSWY and (b)
CGGWSHW. TGFβ1 was injected at 100, 50, 20, 10, 5, and 0 nM in
HBS-EP buﬀer at a ﬂow rate of 50 μL/min. Sensorgrams represent the
average signal for three injections.1055 dx.doi.org/10.1021/bm101379v |Biomacromolecules 2011, 12, 1051–1057
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insignificant in TGFβ1- conditions for both peptide solutions
andacontrol,indicatingaffinitypeptidesareincapableofbinding
TGFβ1receptors.LuciferaseactivityofTGFβ1þsolutionswas3
orders of magnitude greater than that of respective TGFβ1-
solutions,withnostatisticaldifferencebetweentheactivityofthe
peptide solutions and that of the control media. Thus, the
peptide/TGFβ1 affinity complex does not inhibit the growth
factor receptor signaling, and TGFβ1 incubated with peptides
in monomer solutions retains its bioactivity in the absence of
photoencapsulation.
Soluble Affinity Peptides Protect TGFβ1 During UV Ex-
posure.To further explore the effect of soluble peptides on pro-
tecting TGFβ1 during photopolymerization reactions, a mono-
acrylate solution study was employed, similar to that previously
described. Solutions of PEGMA (Mn = 2000), photoinitiator,
and TGFβ1 were exposed to UV radiation and, subsequently,
assayed via ELISA for TGFβ1 concentration, as were solutions
containing WSHW or KRIWFIPRSSWY (R = 1000) (Figure 5).
For PEGMA solution exposed to UV radiation in the absence of
affinity peptides, TGFβ1 recovery was 75% of the pre-exposure
concentration, while solutions, including WSHW or KRIW-
FIPRSSWY peptides, had a recovery of approximately 100%,
not significantly different from the non-UV exposure condition
(t test, p < 0.05.) These results confirm affinity peptides offer a
protective effect for the encapsulated proteins during photo-
polymerization reactions. The mechanism of this protection is
unknown, but one might speculate that it helps shield reactive
sites on TGFβ1, preventing undesirable protein-polymer con-
jugation. Further, the inclusion of these affinity peptides in
monomer solutions should presumably increase the total frac-
tional release of encapsulated growth factor from PEGDA
hydrogels, as their presence in acrylate solutions provides an
increase in recoverable TGFβ1.
Affinity Peptides Increase Fractional Release of Encapsu-
lated TGFβ1. To characterize the effect of affinity peptides on
TGFβ1 release from PEG hydrogels, the growth factor was
encapsulated in monomer solutions of PEGDA (Mn = 10000)
with or without affinity peptides. Control gels (no peptide) and
affinity gels (WSHW or KRIWFIPRSSWY at R = 1000) were
monitored over a four-day time frame (Figure 6a). Of the three
conditions, control gels exhibited the lowest fractional release of
growth factor, with only 12.7 ( 1.2% of the TGFβ1 payload
released by day four. Affinity peptide gels released a larger frac-
tion of the encapsulated growth factor; WSHW gels released
30.4 ( 5.3% and KRIWFIPRSSWY gels with 60.3 ( 5.8% of
encapsulated TGFβ1 over the same time interval. Interestingly,
the release from KRIWFIPRSSWY peptide gels is much greater
than that of gels with WSHW, although the two peptides exhibit
similar dissociation constants (Table 3). Because the two affinity
peptides differ in size and isoelectric point, the difference in frac-
tional release between the two affinity systems may be partially
attributable to changes in the solubility of the TGFβ1-peptide
complex, relative to unbound growth factor. However, TGFβ1
consists of two identical 112 amino acid chains, and the affinity
peptides are 4 or 12 amino acids, so it is less clear of their effects
on the overall protein solubility. While SPR techniques quantify
binding strength between TGFβ1 and a given peptide, the
photoencapsulation reaction is complicated by the inclusion of
PEGDA monomer and initiator species. To confirm that differ-
ences in release between KRIWFIPRSSWY and WSHW gels
were not due to bulk material differences, the shear modulus was
measured for equilibrium swollen PEGDA gels to elucidate any
potential differences in the cross-linking density. Rheometric data
showed inclusion of either affinity peptide in monomer solution
did not significantly affect the swollen shear modulus, G0, of the
resulting polymer (Supporting Information). Thus, increased
TGFβ1 release from peptide gels was not attributed to bulk
differences in hydrogel cross-linking density. These results provide
confirmationthat affinitypeptidesequences WSHWandKRIW-
FIPRSSWY increase the amount of TGFβ1 recovered from
PEGDA hydrogels.
The presence of soluble peptides (R = 1000) in monomer
solutions of TGFβ1 and PEGDA (Mn = 10000) also increased
bioactive growth factor release over a 24 h period, as seen in
Figure 6b. While ELISA-based techniques allow for quantiﬁca-
tion of the total released growth factor, the method utilizes
antibody-based recognition of speciﬁc binding epitopes on the
target protein. To conﬁrm that TGFβ1 released from PEGDA
hydrogels was structurally functional, a cellular recognition assay
was required. PE.25 cells incubated with control gels with no
aﬃnity peptide had luciferase activity twice that of negative con-
Table 3. Aﬃnity Peptide/TGFβ1 Kinetic Parameters Calcu-
lated from SPR Analysis
peptide sequence kd   10
4 (s
-1) KD
CGGWSHW 9.85 8.20
CGGKRIWFIPRSSWY 8.22 10.41
Figure 4. Aﬃnity binding peptides WSHW or KRIWFIPRSSWY do
not inhibit TGFβ1 receptor signaling in media supplemented with
TGFβ1, and peptides do not ellicit a response from PE.25 cells in
TGFβ1 deﬁcient media. Error bars represent standard error (n = 4).
Figure 5. Aﬃnity peptides protect TGFβ1 during photoencapsulation.
Soluble aﬃnity peptides, added to a monomer solution of 20 mM PEG
(Mn = 2000 Da) monoacrylate and photoinitiator, increase the amount
of recovered TGFβ1 after UV exposure. * indicates p < 0.05 (n = 4) for
each peptide concentration, relative to solution containing no peptide.
Error bars represent standard error (n = 4).1056 dx.doi.org/10.1021/bm101379v |Biomacromolecules 2011, 12, 1051–1057
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trolconditions(TGFβ1-),whilecellscoculturedwithgelsencap-
sulated with WSHW (R = 1000) had three times higher activity,
and KRIWFIPRSSWY gels produced 5 times greater luciferase
activity in the reporter cells. This result correlates to the trend in
amount of TGFβ1 released (as measured with ELISA) over the
same24htimeframeinFigure6a.Solubleaﬃnitypeptides,when
included in monomer solutions prior to polymerization, are
shown to increase the amount of bioactive TGFβ1 released from
PEG hydrogels.
Further, fractional release of TGFβ1 was increased when the
peptide concentration in the monomer formulation was in-
creased(Figure7).Thegrowthfactorwasencapsulatedat25nM
in PEDGA (Mn = 10000) for all studies, and the relative molar
ratio of soluble peptide/TGFβ1 was varied from a low concen-
trationof2.5μM(R=100)toamaximumpeptideconcentration
of 250 μM( R = 10000). Gels encapsulated with aﬃnity peptides
WSHW or KRIWFIPRSSWY had the highest fractional release
over a two-day timespan with a ratio of R = 10000, and lower
fractional release was observed at lower ratios. At R = 10000, the
inclusion of the WSHW peptide resulted in 58.8 ( 4.8%
recovery, while KRIWFIPRSSWY (R = 10000) gel exhibited
complete release (115 ( 15.5%) of encapsulated TGFβ1 over a
two day timespan. In conjunction with the monoacrylate studies
on TGFβ1 recovery, these ﬁndings indicate that the presence of
aﬃnity peptides can be used to increase the amount of soluble
and bioactive TGFβ1 in encapsulated hydrogels, resulting in
more predictable delivery and higher total fractional release.
’CONCLUSION
ConditionstomaximizereleaseofthehumancytokineTGFβ1
from photopolymerized PEG diacrylate hydrogel encapsulation
were studied systematically. In solution studies, high acrylate
concentration, greater than 20 mM, showed an increase in
recoverable TGFβ1 but a lowered bioactivity via cell activity
assays. Inclusion of aﬃnity binding peptide sequences in mono-
mer solutions, prior to photoencapsulation, allowed a higher
total release of TGFβ1 from PEG hydrogels, as well as increased
bioactivity of released protein. The inclusion of soluble peptides
provides a facile method for increasing the net recovery of
encapsulated TGFβ1 in applications demanding localized and
sustained delivery, such as tissue regeneration and wound
healing.
’ASSOCIATED CONTENT
b S Supporting Information. (S01) MALDI-TOF spectra
for peptides used; (S02) Hydrodynamic radius estimates from
Stokes-Einstein at 20 C; (S03) Selected protein molecular
weights and hydrodynamic radii; (S04) Swollen shear modulus
forpeptideandcontrolpolymers.Thismaterialisavailablefreeof
charge via the Internet at http://pubs.acs.org.
Figure 6. Aﬃnity peptides increase release of encapsulated TGFβ1
fromPEG(Mn=10000Da)hydrogels.(a)Hydrogelsencapsulatedwith
TGFβ and aﬃnity peptides (R = 1000) show greater release than gels
encapsulated with growth factor alone. Error bars represent standard
error (n = 4). (b) When peptides are encapsulated with TGFβ1 in
hydrogels, ahighercellular responseisseenat24h,relativetohydrogels
without TGFβ1 or those with TGFβ1 and no peptide. * represents p <
0.05 (n = 4) relative to TGFβ1 positive gels with no aﬃnity peptides.
Figure 7. Increased concentration of aﬃnity peptides increases release
ofencapsulatedTGFβ1fromPEG(Mn=10000Da)hydrogels.Forboth
(a) WSHW and (b) KRIWFIPRSSWY peptides, high concentrations of
peptide (R = 10000) results in maximum release of encapsulated
TGFβ1. For KRIWFIPRSSWY, 100% fractional release is achieved in
1 day at R = 10000, while R = 100 gels only released 6.4 ( 1% over a 2
day time span. For WSHW gels, R = 10000 gels achieved 58.8 ( 5%
release in 2 days, while R = 100 gels only released 10.6 ( 1% of their
payload in the same time. Error bars represent standard error (n = 4).1057 dx.doi.org/10.1021/bm101379v |Biomacromolecules 2011, 12, 1051–1057
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